Product Description
Rifaximin is a broad spectrum oral antibiotic with antimicrobial activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. It is poorly absorbed and thus has a highly favorable safety profile. Rifaximin has been shown to be effective in the treatment of traveler's diarrhea, functional bloating and irritable bowel syndrome, small bowel bacterial overgrowth and in the prevention of recurrent overt hepatic encephalopathy (Sourced from: https://pubmed.ncbi.nlm.nih.gov/27547007/)
Mechanisms of Action: RNA polymerase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Lebanon | Luxembourg | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Bausch Health Americas
Company Location: QUEBEC A8 H7L 4A8
Company CEO: Thomas J. Appio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Bulgaria, Canada, France, Germany, Hungary, India, Italy, Japan, Kenya, Korea, Mongolia, New Zealand, Poland, Puerto Rico, Spain, United Kingdom, United States
Active Clinical Trial Count: 12
Highest Development Phases
Phase 3: Brain Diseases|Hepatic Encephalopathy|Liver Cirrhosis|Peritonitis
Phase 2: Acute Respiratory Distress Syndrome|Anemia, Sickle Cell|Diverticulitis|Parkinson's Disease|Rosacea
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RNLC3132 | P3 |
Unknown Status |
Hepatic Encephalopathy |
2026-06-30 |
|
| RED-C-3132 | P3 |
Active, not recruiting |
Brain Diseases|Hepatic Encephalopathy |
2026-01-01 |
57% |
| RED-C-3132 | P3 |
Active, not recruiting |
Brain Diseases|Hepatic Encephalopathy |
2026-01-01 |
57% |
| S66407 | P2 |
Unknown Status |
Acute Respiratory Distress Syndrome |
2025-09-30 |
|
| RED-C-3131 | P3 |
Active, not recruiting |
Brain Diseases|Hepatic Encephalopathy |
2025-09-01 |
57% |
| RED-C-3131 | P3 |
Active, not recruiting |
Brain Diseases|Hepatic Encephalopathy |
2025-09-01 |
57% |